6th IAS Conference On HIV Pathogenesis, Treatment and Prevention

Late Breaker Track B WELBB

Type:
Oral Abstract Session Back
Venue: SR 1
Time: 16:30 - 17:30, 20.07.2011
Code: WELBB
Chairs: Tendani Gaolathe, Botswana
Roy Gulick, United States



Presentations in this session:

16:30
WELBB01
Abstract
Powerpoint
Slides with audio
Risk of progression to AIDS or death in relation to CD4 cell levels in HIV-infected adults with a suppressed viral load under cART
Presented by Heiner C. Bucher, Switzerland
H.C. Bucher, J. Young, on behalf of COHERE
Basel Institute for Clinical Epidemiology and Biostatistics, Basel, Switzerland

16:40
WELBB02
Abstract
Powerpoint
Slides with audio
Impact of tuberculosis (TB) screening and isoniazid preventive therapy (IPT) on incidence of TB and death in the TB/HIV in Rio de Janeiro (THRio) study
Presented by Valeria Saraceni, Brazil
B. Durovni1,2, V. Saraceni1, A. Pacheco3, S. Cavalcante1,3, S. Cohn4, B. King4, L. Moulton4, R. Chaisson4, J. Golub4, THRio study group
1Rio de Janeiro City Health Secretariat, Rio de Janeiro, Brazil, 2Federal University of Rio de Janeiro, Rio de Janeiro, Brazil, 3Fiocruz, Rio de Janeiro, Brazil, 4Johns Hopkins University, Baltimore, United States

16:50
WELBB03
Abstract
Powerpoint
Slides with audio
SWIFT study: switching from lamivudine/abacavir (3TC/ABC) to emtricitabine/ tenofovir DF (FTC/TDF) maintained efficacy and reduced virologic failure
Presented by Edwin DeJesus, United States
R. Campo1, E. DeJesus2, H. Khanlou3, H. Wang4, K. White4, L. Dau4, J. Flaherty4, T. Fralich4
1University of Miami School of Medicine, Division of Infectious Diseases, Miami, United States, 2Orlando Immunology Center, Orlando, United States, 3AIDS Healthcare Foundation, Los Angeles, United States, 4Gilead Sciences, Foster City, United States

17:00
WELBB04
Abstract
Powerpoint
Evaluation of a novel point of care cryptococcal antigen (CRAG) test on serum, plasma and urine from patients with HIV-associated cryptococcal meningitis
Presented by Joseph Nicholas Jarvis, United Kingdom
J.N. Jarvis1,2, A. Percival3, S. Bauman4, G. Meintjes5,6,7, G.N. Williams5, N. Longley1,2,5, T. Harrison1, T. Kozel3
1St George's University of London, Research Centre for Infection and Immunity, London, United Kingdom, 2Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa, 3University of Nevada School of Medicine, Department of Microbiology and Immunology, Reno, United States, 4Immuno-Mycologics (IMMY), Oklahoma, United States, 5GF Jooste Hospital, Infectious Diseases Unit, Cape Town, South Africa, 6University of Cape Town, Faculty of Health Sciences, Institute of Infectious Diseases and Molecular Medicine, Cape Town, South Africa, 7Imperial College London, Department of Medicine, London, United Kingdom

17:10
WELBB05
Abstract
Powerpoint
Slides with audio
Elvitegravir once-daily is non inferior to raltegravir twice-daily in treatment experienced patients: 48 week results from a phase 3 multicenter, randomized, double blind study
Presented by Jean-Michel Molina, France
J.-M. Molina1, A. LaMarca2, J. Andrade Villanueva3, B. Clotet4, N. Clumeck5, Y.-P. Liu6, L. Zhong6, A. Cheng6, J. Szwarcberg6, S.L. Chuck6, for the Study 145 Group
1Hopital Saint Louis, Paris, France, 2Therafirst Medical Center, Fort Lauderdale, United States, 3Hospital Civil de Guadalajara, CUCS, U de G, Guadalajara, Mexico, 4Hospital Universitario Germans Trias i Pujol, Barcelona, Spain, 5C.H.U. St Pierre, Brussels, Belgium, 6Gilead Sciences, Foster City, United States

17:20
Moderated discussion





Powerpoints presentations
Risk of progression to AIDS or death in relation to CD4 cell levels in HIV-infected adults with a suppressed viral load under cART - Heiner C. Bucher

Impact of tuberculosis (TB) screening and isoniazid preventive therapy (IPT) on incidence of TB and death in the TB/HIV in Rio de Janeiro (THRio) study - Valeria Saraceni

SWIFT study: switching from lamivudine/abacavir (3TC/ABC) to emtricitabine/ tenofovir DF (FTC/TDF) maintained efficacy and reduced virologic failure - Edwin DeJesus

Evaluation of a novel point of care cryptococcal antigen (CRAG) test on serum, plasma and urine from patients with HIV-associated cryptococcal meningitis - Joseph Nicholas Jarvis

Elvitegravir once-daily is non inferior to raltegravir twice-daily in treatment experienced patients: 48 week results from a phase 3 multicenter, randomized, double blind study - Jean-Michel Molina



Rapporteur report

Track B report by Roy M. Gulick,


This year, investigators reported on clinical progression in patients on ART with virologic suppression; TB/death with isoniazid preventive therapy; a switch study of nucleoside analogue combinations; a point-of-care test for Cryptococcal antigen; and a randomized study of elvitegravir, an investigational integrase inhibitor, in treatment-experienced patients.
COHERE is a multinational cohort collaboration that was used to assess the risk for progression to AIDS/death in patients on ART with virologic suppression (WELBB01). Following over 75,000 patients for a median of 2.7 years, the investigators found the hazard for disease progression was reduced per CD4 100 cell/uL increase in all groups, with the greatest benefit (65% reduction) seen in patients with CD4 <200/uL.  
THRio is a randomized study of 12,926 patients in 29 clinics in Rio de Janiero testing the use of isoniazid to prevent tuberculosis (WELBB02). The control period was the time prior to a patient presenting to a clinic starting isoniazid preventive therapy; the intervention was time after that visit. Overall, isoniazid decreased tuberculosis or death 11% (intent-to-treat) and 37% (modified intent-to-treat, including only those with annual contact). The authors felt this supported scale-up of isoniazid preventive therapy.
SWIFT is a prospective, multicenter, randomized study of switching the nucleoside analogue backbone (WELBB03). 311 patients taking abacavir/lamivudine and a ritonavir-boosted protease inhibitor with HIV RNA <200 copies/ml for at least 3 months were randomized to continue abacavir/lamivudine or change to tenofovir/emtricitabine. Through 48 weeks, HIV RNA was suppressed to <200 copies/ml in 83% (abacavir) vs. 87% (tenofovir); virologic failure occurred in 11 (abacavir) vs. 3 (tenofovir) patients. The investigators concluded the switch to tenofovir/emtricitabine maintained virologic suppression and reduced the risk of virologic failure.
A study from South Africa assessed plasma, serum and urine from 62 patients with active or recent cryptococcal disease with a quantitative ELISA test and a dipstick lateral-flow assay that both used the same monoclonal antibodies to detect glucuronoxylomannan (GXM) (WELBB04). All patients had detectable GXM using the ELISA and the dipstick test was positive in 61 of 62 patients, with results strongly correlated. The authors felt the simple dipstick could be used to improve early diagnosis of cryptococcal disease.
A phase 3, multicenter, double-blind study reported results in treatment-experienced patients were randomized to optimized background therapy plus either elvitegravir 150 mg daily (or 85 mg if with atazanavir or lopinavir) or raltegravir 400 mg bid (WELBB05). By 48 weeks, HIV RNA was <50 copies/ml in 59% (elvitegravir) and 58% (raltegravir), with 26% (elvitegravir) and 20% (raltegravir) developing integrase inhibitor resistance. The authors concluded that elvitegravir was non-inferior to raltegravir, with a pre-specified threshold for difference of -10%.
 



   

    The organizers reserve the right to amend the programme.


Contact Us | Site map © 2011 International AIDS Society